Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 7/9/13  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Anders Heijl

Wrong Dr. Anders Heijl?

Honorary Member

Company Description: The Glaucoma Research Society is a public interest, non-profit scientific association of outstanding glaucoma researchers that provides a forum to discuss and...   more
Background

Employment History

  • Professor and Chairman, Department of Ophthalmology
    University of Lund , Sweden
  • Chairman of the Department of Ophthalmology
    Malmö University Hospital

Education

  • M.D.
  • Ph.D.
  • MD
  • PhD
31 Total References
Web References
Dr. Anders ...
www.glaucomasociety.org, 9 July 2013 [cached]
Dr. Anders Heijl
...
Dr. Anders Heijl, Sweden
Carl Zeiss Meditec Introduces New Innovations: ‘Creating What’s to Come’ at AAO 2010 - CoActive
www.coactivepr.com, 16 Oct 2010 [cached]
"Clinical assessment of glaucoma patients, or particularly patients who have suspect glaucoma, requires assessment of visual function test results and structural parameters comparing both diagnostic modalities in each eye," said Anders Heijl, MD, PhD, Professor and Chairman, Department of Ophthalmology, University of Lund, Sweden.
Glaucoma Treatment
www.tricountyeye.com, 27 Sept 2007 [cached]
These results should be put into perspective, according to Anders Heijl, M.D., Ph.D., chairman of the Department of Ophthalmology at Sweden's Malmö University Hospital and first author of the report. "Although the study closely checked for possible glaucoma progression, many of the patients remained stable over time, even those in the control group," Dr. Heijl said. "On the other hand, despite the clear effect of treatment, glaucoma progressed in as many as 30 percent of treated patients after four years."
Dr. Heijl said that the time it took for glaucoma to progress varied greatly among patients and was sometimes rather short, even in treated patients. "This shows that in many patients with rapidly progressing glaucoma, the treatment used in this study was insufficient to halt progression of the disease," Dr. Heijl said. Dr. Heijl emphasized that treatment for early, newly diagnosed glaucoma should be individualized and carefully balanced. Before deciding on the best treatment option, eye care professionals should consider several unique patient factors, such as age, eye pressure levels, and disease severity. "The study findings support the medical community's growing contention that glaucoma treatment should be tailored to the individual needs of the patient," Dr. Heijl said.
Anders ...
www.glaucomasociety.org, 9 July 2013 [cached]
Anders Heijl
...
Dr. Anders Heijl
...
Dr. Anders Heijl, Sweden
Immediate Treatment Helps Delay Progression of Glaucoma [NEI News and Events]
www.nationaleyeinstitute.org, 14 Oct 2002 [cached]
These results should be put into perspective, according to Anders Heijl, M.D., Ph.D., chairman of the Department of Ophthalmology at Sweden's Malmö University Hospital and first author of the report. "Although the study closely checked for possible glaucoma progression, many of the patients remained stable over time, even those in the control group," Dr. Heijl said. "On the other hand, despite the clear effect of treatment, glaucoma progressed in as many as 30 percent of treated patients after four years."
Dr. Heijl said that the time it took for glaucoma to progress varied greatly among patients and was sometimes rather short, even in treated patients. "This shows that in many patients with rapidly progressing glaucoma, the treatment used in this study was insufficient to halt progression of the disease," Dr. Heijl said.
Dr. Heijl emphasized that treatment for early, newly diagnosed glaucoma should be individualized and carefully balanced. Before deciding on the best treatment option, eye care professionals should consider several unique patient factors, such as age, eye pressure levels, and disease severity. "The study findings support the medical community's growing contention that glaucoma treatment should be tailored to the individual needs of the patient," Dr. Heijl said.
...
Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M, Early Manifest Glaucoma Trial Group. Reduction of Intraocular Pressure and Glaucoma Progression: Results From The Early Manifest Glaucoma Trial.
Other People with the name "Heijl":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304